ERBB2 and neoplasm: Subtype classification of patients with metastatic HR+/HER2+ tumours using the PAM50 gene signature could be used as a useful tool for identifying patients with Luminal A tumours that exhibit longer progression-free survival (PFS) among other subtypes (Prat et al. 2016).